Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Shire LLC, Supernus Pharmaceuticals, Incl et al v. IMPAX Laboratories, Inc. et al
Case Number:
3:10-cv-05467
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
June 14, 2013
Shire Settles Intuniv Infringement Case Against Impax
Impax Laboratories Inc. has agreed to license Shire PLC's patents for the attention deficit hyperactivity disorder drug Intuniv, resolving Shire's infringement litigation over Impax's bid to launch a generic version of the drug, according to settlement papers filed Thursday in California federal court.
-
August 29, 2011
Shire Patent Suit Over Generic Intuniv Survives
A California federal judge on Monday denied Impax Laboratories Inc. and Watson Pharmaceuticals Inc.'s attempt to dismiss a patent infringement suit brought by Irish drugmaker Shire PLC over a generic version of its attention deficit hyperactivity disorder drug Intuniv.